Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
John Cavenagh, PhD, PA-C
OBJECTIVE: The objective of this selective EBM review is to determine whether or not oral rivaroxaban is safe and effective in the treatment of patients with symptomatic DVT.
STUDY DESIGN: Review of three English language primary randomized controlled trial studies published from 2007-2011.
DATA SOURCES: Three randomized controlled trials studying the effectiveness and safety of rivaroxaban in the treatment of patients with symptomatic DVT in comparison to enoxaparin and placebo.
OUTCOMES MEASURED: Outcomes measured were episodes of recurrent DVT and bleeding. Patients were monitored for the proposed treatment period and seen at fixed intervals that were matching for the rivaroxaban and comparison groups. At this time a checklist was used to gather information on symptoms and signs of recurrent venous thromboembolism, bleeding, and adverse events.
RESULTS: The articles showed rivaroxaban is safe and effective in the treatment of patients with deep venous thrombosis. The primary efficacy outcome in all was episodes of recurrent DVT. The principle safety outcome in all studies was clinically relevant major and non-major bleeding.
CONCLUSIONS: This review supports the use of rivaroxaban in the treatment of patients with symptomatic deep venous thrombosis. More information is needed for the use of the drug in special populations such as cancer patients.
Patel, Ami A., "Is Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?" (2013). PCOM Physician Assistant Studies Student Scholarship. 105.